Long-term treatment shows sustained efficacy and safety in Crohn's disease, indicating continued benefits for patients.
Introduction: Mirikizumab (miri), an anti-IL-23p19 antibody, was efficacious and safe as a treatment for moderately-to-severely active Crohn's disease (CD) over 104 weeks in a Phase 2 study (AMAG; NCT02891226). Here we show continued activity through an additional 3 years (up to 6.5 years total) in a long-term extension study, AMAX (NCT04232553).
No takes yet. Share an insight, caveat, or question.
Sands et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: